A multi-center interventional study to assess pharmacokinetics, effectiveness, and tolerability of prolonged-release tacrolimus after pediatric kidney transplantation: study protocol for a prospective, open-label, randomized, two-phase, two-sequence, single dose, crossover, phase III b trial

BackgroundTacrolimus, a calcineurin inhibitor (CNI), is currently the first-line immunosuppressive agent in kidney transplantation. The therapeutic index of tacrolimus is narrow due to due to the substantial impact of minor variations in drug concentration or exposure on clinical outcomes (i.e., nep...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Sinem Karaterzi, Burkhard Tönshoff, Thurid Ahlenstiel-Grunow, Maral Baghai, Bodo Beck, Anja Büscher, Lisa Eifler, Thomas Giese, Susanne Lezius, Carsten Müller, Jun Oh, Antonia Zapf, Lutz T. Weber, Lars Pape
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2024-02-01
Sarja:	Frontiers in Nephrology
Aiheet:	tacrolimus Prograf® Envarsus® pharmacokinetics pharmacodynamics pharmacogenetics
Linkit:	https://www.frontiersin.org/articles/10.3389/fneph.2024.1331510/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!